Novartis Investigative Site

The Hague, South Holland 2545 AA

2 studies enrolling now · 5 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Disease and Lipoprotein(a), Primary Prevention of Atherosclerotic Cardiovascular Disease, Sickle Cell Disease (SCD)

Studies at this site

• Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD — Recruiting now
• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling